AVITA MED LTD/S (NASDAQ: RCEL) is one of 129 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare AVITA MED LTD/S to related businesses based on the strength of its analyst recommendations, earnings, valuation, risk, dividends, profitability and institutional ownership.
This table compares AVITA MED LTD/S and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AVITA MED LTD/S||N/A||N/A||N/A|
|AVITA MED LTD/S Competitors||-4,130.44%||-82.52%||-35.59%|
AVITA MED LTD/S has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, AVITA MED LTD/S’s peers have a beta of 1.64, meaning that their average stock price is 64% more volatile than the S&P 500.
Valuation and Earnings
This table compares AVITA MED LTD/S and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AVITA MED LTD/S||$5.51 million||-$24.75 million||-24.87|
|AVITA MED LTD/S Competitors||$785.24 million||$155.67 million||5.42|
AVITA MED LTD/S’s peers have higher revenue and earnings than AVITA MED LTD/S. AVITA MED LTD/S is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
0.0% of AVITA MED LTD/S shares are owned by institutional investors. Comparatively, 50.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 18.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent ratings and recommmendations for AVITA MED LTD/S and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AVITA MED LTD/S||0||0||1||0||3.00|
|AVITA MED LTD/S Competitors||1101||3343||6957||310||2.55|
AVITA MED LTD/S presently has a consensus price target of $12.00, suggesting a potential upside of 23.71%. As a group, “Biological products, except diagnostic” companies have a potential upside of 41.65%. Given AVITA MED LTD/S’s peers higher possible upside, analysts clearly believe AVITA MED LTD/S has less favorable growth aspects than its peers.
AVITA MED LTD/S peers beat AVITA MED LTD/S on 8 of the 13 factors compared.
About AVITA MED LTD/S
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients 18 years and older. The company is based in Valencia, California.
Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.